Skip to content

Clinical trials

Observational Cardiomyopathies trials

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Cardiomyopathies Phase: Observational Clear all

271 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20001
20012
20023
20033
20044
20052
20069
20077
20088
20095
201015
20116
20125
20137
201412
201511
20167
20178
201817
20199
202016
202119
202217
202322
202422
20259
202617

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed111
Recruiting68
Unknown status53
Active, not recruiting13
Not yet recruiting8
Terminated8
Enrolling by invitation8
Withdrawn2

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
National Heart, Lung, and Blood Institute (NHLBI)12
University Hospital, Bonn6
Assistance Publique - Hôpitaux de Paris5
IRCCS Azienda Ospedaliero-Universitaria di Bologna5
Mayo Clinic5
Assiut University4
Emory University4
Imperial College London4
Medtronic Cardiac Rhythm and Heart Failure4
Abbott Medical Devices3

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Cardiomyopathies271
Heart Failure76
Heart Diseases30
Cardiovascular Diseases28
Arrhythmias, Cardiac27
Death, Sudden, Cardiac21
Myocarditis20
Cardiomyopathy, Dilated17
Cardiomyopathy, Hypertrophic16
Amyloidosis14

Trials

Showing 51 to 75 of 271. Each trial links to its page on Pharma Observatory.

171 more trials match. See them on Pharma Observatory

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.